Flamel Technologies is a specialty pharmaceutical company with a long history of expertise in drug delivery, focusing on the development of safer and more efficacious formulations, tackling unmet medical needs in the process.
Controlled release of injected biologics and small molecules drugs.
Controlled release oral liquid drugs.
Controlled release of oral drugs.
Tamper-resistant controlled release formulations of narcotics and other drugs prone to abuse.
Flamel Technologies currently markets Bloxiverz (a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery) in the USA and has nine more proprietary products in its pipeline.
As a publicly-held company, Flamel Technologies strives to use its technologies to create extraordinary shareholder value.